JP Morgan Maintains Overweight on NeuroPace, Raises Price Target to $20

Benzinga · 2d ago
JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the price target from $18 to $20.